Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
Author: Marshall, H.
Richmond, P.
Nissen, M.
Wouters, A.
Baber, J.
Jiang, Q.
Anderson, A.
Jones, T.
Harris, S.
Jansen, K.
Perez, J.
Citation: Vaccine, 2013; 31(12):1569-1575
Publisher: Elsevier Sci Ltd
Issue Date: 2013
ISSN: 0264-410X
Statement of
Helen S. Marshall, Peter C. Richmond, Michael D. Nissen, Ann Wouters, James Baber, Qin Jiang, Annaliesa S. Anderson, Thomas R. Jones, Shannon L. Harris, Kathrin U. Jansen, John L. Perez
Abstract: <h4>Background</h4>Neisseria meningitidis serogroup B (MnB) is a leading cause of bacterial meningitis and septicemia in adolescents and young adults. No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease. A bivalent rLP2086 vaccine based on two factor H-binding proteins (fHBPs) has been developed to provide broad protection against MnB disease-causing strains.<h4>Methods</h4>This study assessed the safety and immunogenicity of the final formulation of a bivalent rLP2086 vaccine in 60 healthy adults (18-40 years of age) receiving 120 μg doses at 0, 1, and 6 months. Safety was assessed by collecting solicited reactogenicity data and participant-reporting of adverse events. Immunogenicity was evaluated by human serum bactericidal assay (hSBA) against 5 MnB strains expressing distinct fHBP variants and fHBP-specific immunoglobulin G titre.<h4>Results</h4>After each immunisation, local reactions such as pain at the injection site and erythema were generally mild or moderate. The most common vaccine-related adverse event was upper respiratory tract infection, which was reported by two participants. Seroprotection (hSBA titres ≥ 1:4) was achieved in 94.3% of participants against a MnB strain expressing the vaccine-homologous fHBP variant A05 and 70.0%-94.7% against MnB strains expressing the heterologous fHBP variants B02, A22, B44, and B24. Seroconversion rates (≥ 4-fold rise in hSBA titres) ranged from 70.0% to 94.7% across the five MnB test strains following the 3-dose vaccination regimen. Immunogenicity responses tended to increase upon subsequent vaccine doses.<h4>Conclusions</h4>Bivalent rLP2086 is a promising vaccine candidate for broad protection against MnB disease-causing strains.
Keywords: Meningococcal vaccines; Bacterial outer membrane proteins; Bactericidal antibodies; Factor H binding protein; Serum bactericidal assay; Neisseria meningitidis serogroup B
Rights: © 2013 Elsevier Ltd. All rights reserved.
RMID: 0020124743
DOI: 10.1016/j.vaccine.2013.01.021
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.